Tinnitus
Clinical Snapshot
Tinnitus is the perception of sound in the absence of any external stimulus — patients describe it as ringing, hissing, whistling, humming, buzzing, chirping, or clicking.[1] It is genuinely common: an estimated 41% of people aged 3 to 79 will experience tinnitus at least once in their lifetimes, most often older adults, and roughly 1 in 5 patients who experience it report it as genuinely bothersome — associated with decreased sleep, impaired concentration, or a worsened mood.[1] That bothersome/nonbothersome distinction matters clinically: most people with tinnitus need only reassurance, while a bothersome, persistent presentation is where the evidence-based therapies in this chapter (see Non-Pharmacologic Treatment) genuinely change quality of life.
Two classification questions structure essentially the entire diagnostic approach and are worth asking, explicitly, in every patient. The first is pulsatile versus nonpulsatile: nonpulsatile tinnitus is by far the more common presentation, is typically subjective (heard only by the patient), and is usually related to hearing loss of some kind; pulsatile tinnitus is often heartbeat-synchronous, can sometimes be objective (audible to an examiner on auscultation), and — unlike routine subjective tinnitus — specifically warrants a vascular and structural imaging workup, since its differential includes a dural arteriovenous fistula, arteriovenous malformation, carotid pathology, a glomus tumour, or a venous sinus abnormality (see Recognize the Condition and Red Flags & Refer).[1][2] The second is unilateral versus bilateral: bilateral, symmetric tinnitus is the pattern most consistent with routine age-related or noise-related hearing loss, while unilateral tinnitus — or tinnitus accompanied by asymmetric hearing loss — is a red flag warranting audiology referral and imaging to exclude a vestibular schwannoma, exactly as in the Hearing Loss chapter's own asymmetric-hearing-loss red flag.[1]
This chapter also gives genuine centerpiece weight to drug-induced ototoxicity, because tinnitus itself — not a change on formal audiometry — is very often the earliest, most practical, patient-reportable warning sign that an ototoxic drug is causing harm, sometimes appearing before any measurable hearing threshold shift.[3] See Risk Factors and Drug Tables for a genuinely detailed, agent-by-agent breakdown. Finally, this chapter states plainly, rather than glossing over, an honest and important expectation-setting point: for most patients with chronic tinnitus (symptoms lasting more than 6 months), there is no cure, because the underlying cause is typically hearing loss that is itself not reversible — the goal of management is not eliminating the sound, but reducing its impact on the patient's life through evidence-based non-pharmacologic therapy, amplification where indicated, and active management of any comorbid anxiety, depression, or sleep disturbance.[1] This chapter is deliberately scoped to tinnitus itself; for the full ototoxicity-monitoring protocol and sudden sensorineural hearing loss, see the Hearing Loss chapter, and for the specific endolymphatic-hydrops tetrad of episodic vertigo, fluctuating hearing loss, tinnitus, and aural fullness, see the Ménière's Disease chapter.
Recognize the Condition
Subjective (nonpulsatile) tinnitus — the common presentation
Subjective tinnitus is only heard by the patient and accounts for the large majority of presentations. It is typically related to some form of hearing loss — most often age-related presbycusis or noise-induced hearing loss, both usually gradual and bilateral, but also, importantly for this chapter, drug-induced ototoxicity (see Risk Factors and Drug Tables).[1] Bilateral, symmetric subjective tinnitus without other red-flag features is the pattern most consistent with routine hearing loss and generally does not require imaging.[2] Unilateral subjective tinnitus, even without a pulsatile quality, is treated differently — see Red Flags & Refer.
Objective (pulsatile) tinnitus — often heartbeat-synchronous, sometimes audible to an examiner
Pulsatile tinnitus is a distinct subtype, representing roughly 5-10% of all tinnitus presentations, characterized by a perception of heartbeat-synchronous sound; it is often, though not always, objective — capable of being heard by an examiner on auscultation.[2] Within pulsatile tinnitus, a further distinction matters: pulse-synchronous tinnitus (typically vascular in origin) versus pulse-asynchronous, or "pseudo-pulsatile," tinnitus caused by palatal muscle contraction or tensor tympani/stapedius muscle spasm (myoclonus) rather than a vascular source.[1][2] This distinction is genuinely important because pulse-synchronous pulsatile tinnitus specifically warrants a vascular and structural imaging workup that routine subjective tinnitus does not (see Red Flags & Refer and Assessment & Diagnosis).
Natural history — set honest expectations early
For most patients with chronic tinnitus (symptoms present for more than 6 months), there is genuinely no cure, because the symptom is a downstream consequence of hearing loss that is itself typically not reversible.[1] Longitudinal outcome data bear this out: at 5-year follow-up, roughly 14% of patients reported worsening symptoms, 18% reported improvement, and complete resolution occurred in only about 16% of patients.[1] This is not a reason for therapeutic nihilism — see Non-Pharmacologic Treatment for what genuinely does help — but patients deserve this honest framing from the outset rather than an implied promise that tinnitus will simply go away or that a drug exists to cure it (see Choose Initial Treatment).
Risk Factors
General risk factors
- Age — prevalence rises with age, peaking in the 60- to 69-year age range.[1]
- Obesity (BMI ≥30 kg/m²), smoking, diabetes mellitus, and hypertension — all recognized associated risk factors.[1]
- Noise exposure, occupational or recreational, and prior acoustic trauma — cross-reference the Hearing Loss chapter's prevention content (the 80-to-90 rule and hearing protection are covered in Non-Pharmacologic Treatment below).
- Pre-existing or comorbid hearing loss of any cause — the single most common underlying driver of subjective tinnitus.
- Mood disorders — anxiety and depression both worsen the perceived severity and quality-of-life impact of tinnitus, and the relationship runs in both directions (see Special Populations and Monitoring & Follow-Up).
Ototoxic-drug risk factors — the pharmacist-critical core of this chapter
Tinnitus is very often the earliest clinical sign of drug-induced ototoxicity — frequently appearing before any change is detectable on formal audiometry — which makes it a genuinely practical, low-cost, patient-reportable warning sign that a pharmacist is well positioned to ask about at every relevant contact.[3] As in the Hearing Loss chapter, ototoxicity severity is generally dose-dependent and cumulative, and is influenced by age, renal or cardiac comorbidity, genetic susceptibility, route, duration of therapy, and pre-existing hearing loss.[3] The scale of this problem is genuinely broad: a 2020 comprehensive review catalogued 194 systemically administered medications with evidence of cochleotoxicity, vestibulotoxicity, or dizziness — most commonly antimicrobials, psychotropics, antihypertensives/antiarrhythmics, NSAIDs, and antineoplastics — with tinnitus a frequently reported presenting symptom well beyond the individual agents detailed below.[4]
Ototoxic drug classes and their tinnitus-specific pattern
Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin)
Tinnitus can precede a measurable threshold shift and, critically, aminoglycoside ototoxicity is frequently irreversible — once cochlear or vestibular hair cell injury has occurred, it does not reliably resolve even after the drug is stopped.[5] Concurrent loop diuretic or glycopeptide (e.g., vancomycin) use materially raises this risk — see the Hearing Loss chapter for the full monitoring protocol for this combination.
Loop diuretics (furosemide)
Risk is concentrated in high-dose intravenous use, especially rapid bolus administration. Tinnitus from furosemide alone is typically reversible and self-limited, but the risk becomes additive — and potentially permanent — when combined with a concurrent aminoglycoside.
High-dose salicylates (acetylsalicylic acid)
Tinnitus is classically the earliest and most reliable warning sign of salicylate ototoxicity, and — genuinely useful as a teaching contrast to the aminoglycoside pattern above — is dose-related and typically fully reversible within 24 to 72 hours of dose reduction or discontinuation.
Platinum-based chemotherapy (cisplatin)
Ototoxicity is cumulative-dose dependent and often permanent, frequently presenting with bilateral high-frequency hearing loss accompanied by tinnitus; young children, particularly those under 5, carry materially higher risk.
Quinine
Tinnitus is a hallmark early feature of cinchonism, the classic quinine toxicity symptom cluster, typically appearing within 3 to 6 hours of ingestion alongside nausea, headache, and reversible high-frequency hearing loss.[6] Ototoxicity is dose-related, and in most patients is almost completely reversible with dose reduction or discontinuation — though this should not be assumed automatic with repeated or high-dose exposure.[6]
High-dose or prolonged macrolide antibiotics
Risk is driven by cumulative dose rather than a single short course. A large cohort study found macrolide use overall was associated with about 25% higher odds of tinnitus, an association that strengthened above a cumulative dose of 14 defined daily doses and was most pronounced with intermediate- and long-acting agents (azithromycin, clarithromycin) rather than short-acting ones.[7]
The practical pharmacist takeaway: treat any new patient-reported tinnitus during a course of a known ototoxic agent as a genuine, actionable signal worth escalating promptly to the prescriber — not as a minor or expected nuisance to reassure away. See Choose Initial Treatment, Drug Tables, and the Hearing Loss chapter for the full escalation and monitoring approach.
Red Flags & Refer
- Pulsatile (objective) tinnitus — this chapter's central emergency-recognition message alongside the unilateral flag below. Unlike routine subjective tinnitus, pulsatile tinnitus warrants a dedicated vascular and structural workup, since its differential includes a dural arteriovenous fistula (representing up to 20% of pulse-synchronous cases), an arteriovenous malformation, carotid artery stenosis or dissection, fibromuscular dysplasia, a cerebral aneurysm, a glomus tumour (paraganglioma), idiopathic intracranial hypertension, and structural venous abnormalities such as sigmoid sinus diverticulum/dehiscence or transverse sinus stenosis.[2] See Assessment & Diagnosis for the specific imaging pathway.
- Unilateral tinnitus, or tinnitus with asymmetric hearing loss — even without a pulsatile quality, warrants referral to an otolaryngologist and audiology, since these features might be associated with a more serious underlying condition, most importantly a vestibular schwannoma.[1] A normal otoscopic exam does not rule this out — imaging (screening noncontrast MRI of the internal auditory canals, or referral to otolaryngology) is the next step, not reassurance.[1]
- Abnormal findings on otoscopy in a patient with tinnitus — cerumen impaction, tympanic membrane perforation, chronic otitis media, cholesteatoma, or otosclerosis — also warrants referral to an otolaryngologist to address the identified conductive cause.[1]
- Tinnitus accompanied by episodic vertigo and fluctuating hearing loss and aural fullness, all in the same ear — raises the possibility of Ménière's disease; see the dedicated Ménière's Disease chapter for the full diagnostic criteria and management ladder rather than managing this pattern as routine tinnitus.
- Tinnitus with new focal neurologic signs (diplopia, dysarthria, facial weakness, limb weakness/numbness, ataxia out of proportion to any dizziness) — raises concern for a central cause such as multiple sclerosis, a cerebellopontine angle tumour, or brainstem infarction, and warrants urgent assessment rather than routine ENT referral.[1]
- New tinnitus, or worsening tinnitus, reported during a course of a known ototoxic agent — the pharmacist-specific red flag at the heart of this chapter. Treat this as an early, often still-modifiable warning sign and escalate promptly to the prescriber to weigh dose adjustment, interval change, agent substitution, or discontinuation against the necessity of the causative therapy — not routine reassurance. See Choose Initial Treatment, Drug Tables, and the Hearing Loss chapter.
- Severe, persistent, treatment-refractory tinnitus with significant mental health impact, including any expression of hopelessness or suicidal ideation — screen explicitly and refer urgently per the Suicide Risk & Prevention chapter; do not assume distress this severe will resolve with reassurance or routine non-pharmacologic therapy alone. See Special Populations and Monitoring & Follow-Up.
Assessment & Diagnosis
History
Direct the history at the 2 classification questions that drive the entire work-up: is the tinnitus pulsatile or nonpulsatile, and is it unilateral or bilateral? Also establish whether it is bothersome or nonbothersome, whether hearing loss, vertigo, or other neurologic symptoms accompany it, and — genuinely central to this chapter — take a complete history of past or current ototoxic medication use, along with any history of acoustic trauma or occupational noise exposure.[1] This medication-focused history is one of the most valuable contributions a pharmacist can make to the diagnostic picture.
Physical examination
Perform a cranial nerve examination and otoscopy in every patient.[1] For patients with pulsatile tinnitus specifically, auscultate over the neck, mastoid, and preauricular areas for bruits, and extend auscultation to the orbital and temporal/retroauricular regions when an arteriovenous fistula is suspected.[1][2] A jugular venous compression test is a genuinely useful bedside maneuver in pulsatile tinnitus: venous pulsatile tinnitus tends to be low-pitched and often improves or disappears with gentle compression of the ipsilateral jugular vein, while tinnitus that worsens with compression, or does not change, points instead toward an arterial source.[2] A positive compression response supports, but does not by itself confirm, a benign venous hum — vascular imaging is still reasonable given how broad the differential remains (see below).
Audiologic evaluation
All patients with tinnitus should be referred to an audiologist for a formal audiologic evaluation, to establish auditory function and identify any hearing loss.[1] A comprehensive tinnitus assessment characterizes 4 parameters: pitch, loudness, maskability, and residual inhibition.[1] A validated instrument such as the Tinnitus Handicap Inventory is a genuinely useful adjunct to quantify the functional and quality-of-life impact at baseline and at follow-up, particularly for bothersome tinnitus (see Monitoring & Follow-Up).[3]
Imaging — targeted by tinnitus subtype, not routine
| Presentation | Imaging approach |
|---|---|
| Bilateral, nonpulsatile | Routine imaging is not recommended.[1][2] |
| Unilateral, nonpulsatile, normal otoscopy | Referral to an otolaryngologist, or screening noncontrast MRI of the internal auditory canals, to exclude a vestibular schwannoma.[1] |
| Pulsatile (any laterality) | MRI combined with MRA and MRV of the brain and neck is the most useful first-line test; add CT angiography of the supra-aortic trunks if cervical vascular pathology (e.g., carotid stenosis or dissection) is specifically suspected; high-resolution CT of the temporal bone if MRI is normal but a structural cause (e.g., sigmoid sinus dehiscence) is still suspected; digital subtraction angiography remains the gold standard for detecting an arteriovenous fistula or malformation when noninvasive imaging is negative but suspicion remains high.[1][2] |
Differential diagnosis
| Representative causes by tinnitus type | |
|---|---|
| Nonpulsatile, unilateral — conductive: cerumen impaction, tympanic membrane perforation | Chronic otitis media, otosclerosis, cholesteatoma |
| Nonpulsatile, unilateral — sensorineural: chronic noise exposure, acoustic trauma | Superior semicircular canal dehiscence, Ménière's disease |
| Nonpulsatile, unilateral — complex/central: multiple sclerosis | Cerebellopontine angle tumour (vestibular schwannoma), brainstem infarction |
| Nonpulsatile, bilateral: age-related hearing loss (presbycusis) | Noise exposure/acoustic trauma, otosclerosis, ototoxic drug-induced (see Risk Factors and Drug Tables) |
| Pulsatile — vascular (arterial): arterial bruits, systemic hypertension | Carotid stenosis/dissection, fibromuscular dysplasia, aneurysm, glomus tympanicum/jugulare paraganglioma |
| Pulsatile — vascular (venous): venous hum, idiopathic intracranial hypertension | Arteriovenous malformation/fistula, sigmoid sinus diverticulum or dehiscence |
| Pulsatile — mechanical ("pseudo-pulsatile"): tensor tympani/stapedius muscle spasm | Palatal muscle contraction/myoclonus |
Treatment Targets
- Correctly classify tinnitus as pulsatile versus nonpulsatile and unilateral versus bilateral at the first encounter, since this classification — not the tinnitus itself — is what drives the entire subsequent work-up.
- Identify and refer pulsatile tinnitus for a genuine vascular/structural work-up, and unilateral tinnitus or tinnitus with asymmetric hearing loss for audiology and imaging to exclude a vestibular schwannoma, rather than defaulting either presentation to routine reassurance.
- Identify and address any treatable underlying cause — cerumen impaction, a structural vascular lesion, or an ototoxic medication — wherever one genuinely exists.
- For ototoxic drug-induced tinnitus specifically: recognize it as an early, often still-modifiable warning sign and coordinate with the prescriber on dose adjustment, interval change, agent substitution, or discontinuation, weighed explicitly against the necessity of the causative therapy.
- Set honest, accurate expectations for chronic subjective tinnitus — there is no cure for most patients, and the goal is reducing impact, not eliminating the sound.
- Reduce the bother and quality-of-life impact of persistent tinnitus through the non-pharmacologic therapies with genuine efficacy data — cognitive behavioral therapy, sound therapy, and tinnitus retraining therapy — rather than reaching for unproven or explicitly not-recommended pharmacotherapy.
- Support hearing aid evaluation and amplification for any patient with comorbid hearing loss.
- Screen for and actively address comorbid anxiety, depression, and sleep disturbance as a genuine, important component of care in bothersome tinnitus, not an afterthought.
Choose Initial Treatment
Classify first — the branch point decides the plan
Every new tinnitus presentation establish pulsatile versus nonpulsatile and unilateral versus bilateral before anything else, plus otoscopy and, for pulsatile tinnitus, auscultation for bruits and a jugular compression test.[1][2] Pulsatile, or unilateral, or asymmetric hearing loss, or abnormal otoscopy refer for the specific work-up in Red Flags & Refer and Assessment & Diagnosis — do not manage as routine subjective tinnitus. Bilateral, nonpulsatile, normal otoscopy, no other red flag proceed with the chronic subjective tinnitus pathway below.
Chronic subjective (nonpulsatile) tinnitus
Every patient set honest expectations: for chronic tinnitus (>6 months), there is no cure in most cases, and management is about reducing impact, not eliminating the sound.[1] Identify and treat any genuinely reversible contributing cause (cerumen impaction, an ototoxic medication — see below) before assuming none exists. Nonbothersome reassurance and conservative measures (sound therapy basics, hearing protection) are usually sufficient — see Non-Pharmacologic Treatment.[1] Persistent and bothersome refer for a hearing aid evaluation if hearing loss is present, and recommend cognitive behavioral therapy — genuinely evidence-supported and currently recommended for persistent, bothersome tinnitus.[8][1] Sound therapy and tinnitus retraining therapy are reasonable adjuncts, though the trial evidence supporting sound therapy specifically is graded at the "option" level rather than a full recommendation — disclose this honestly rather than overstating it.[8]
What current guidance explicitly advises against for primary tinnitus
Do not routinely recommend antidepressants, anticonvulsants, or anxiolytics for a primary indication of treating persistent, bothersome tinnitus — current guidance recommends against this specifically.[8] Do not routinely recommend intratympanic medications for primary tinnitus, and do not recommend ginkgo biloba, zinc, or other dietary supplements as a tinnitus treatment.[8] A genuine, worth-disclosing tension exists specifically around melatonin: the Canadian review notes exogenous melatonin has shown symptom improvement, particularly for tinnitus-associated sleep disturbance, while the AAO-HNSF guideline's "recommendation against" for dietary supplements is not agent-specific and would technically include it — the honest position is that melatonin is reasonable as a sleep-focused adjunct in a patient with tinnitus-related insomnia, not as a therapy marketed to "treat the tinnitus" itself.[1][8] Separately, when a patient has a formally diagnosed comorbid depression or anxiety disorder alongside their tinnitus, a tricyclic antidepressant or selective serotonin reuptake inhibitor is a reasonable choice for that diagnosed comorbidity on its own merits — this is treating the depression or anxiety, not the tinnitus itself, and the distinction is worth explaining clearly to the patient.[1][8]
Ototoxic drug-induced tinnitus — the pharmacist's core decision
New or worsening tinnitus reported during a course of a known ototoxic agent escalate to the prescriber promptly — this is genuinely one of the most actionable findings in this entire chapter, since tinnitus frequently precedes a measurable audiometric change.[3] The decision is a genuine risk-benefit discussion (dose reduction, longer interval, agent switch, or discontinuation, weighed against the necessity of the causative therapy), not automatic discontinuation — see the Hearing Loss chapter's Choose Initial Treatment and Monitoring & Follow-Up for the full protocol, which this chapter deliberately does not duplicate.
Pulsatile tinnitus with an identified structural or vascular cause
Management (embolization or resection of a dural arteriovenous fistula or malformation, surgical management of a glomus tumour, venous sinus stenting for idiopathic intracranial hypertension-related stenosis, or carotid intervention where indicated) is directed by neurotology, neurosurgery, or interventional neuroradiology once a structural cause is identified — not a pharmacist decision, but relevant to counseling a patient about what to expect from referral.
Non-Pharmacologic Treatment
Cognitive behavioral therapy — the best-supported therapy for bothersome tinnitus
Recommended CBT aims to correct a patient's negative emotional and behavioral response to tinnitus, primarily through counseling and relaxation techniques, rather than attempting to eliminate the perception of sound itself.[1] It has been shown to improve quality of life and decrease depression in tinnitus sufferers and is currently recommended for persistent and bothersome tinnitus.[1][8]
Sound therapy and masking
- Hearing aids — for a patient with comorbid hearing loss, hearing aids serve a dual role: restoring audibility (see the Hearing Loss chapter for the full amplification discussion) and acting as a masker by introducing ambient sound that reduces the perceived prominence of tinnitus.[1] Current guidance recommends a hearing aid evaluation for any patient with hearing loss and persistent, bothersome tinnitus.[8]
- Dedicated tinnitus maskers and white-noise generators — adjustable nature sounds or broadband noise devices have been shown to decrease perceived tinnitus severity and improve sleep.[1]
- Tinnitus retraining therapy (TRT) — combines directive counseling with ear-level noise generators to help dissociate the tinnitus percept from the patient's negative emotional response to it, distinct from CBT's more purely psychological approach.[1]
Prevention
- The 80-to-90 rule — a genuinely practical, patient-facing primary prevention target: keep personal listening device volume at 80% of maximum, and limit listening to under 90 minutes per day.[1]
- Occlusive headphones reduce the need to raise volume to overcome external noise, which itself lessens delivered sound intensity.[1]
- Noise protection more broadly during and after any planned ototoxic drug course — cross-reference the Hearing Loss chapter's specific counseling on avoiding loud noise exposure during, and for several months after, a course of a known ototoxic agent.
- Dietary factors — reducing carbohydrate and cholesterol intake has been proposed as a way to help prevent age-related hearing loss, though this is a softer, adjunctive recommendation rather than a primary intervention.[1]
Lifestyle and conservative measures
- Improving sleep hygiene, reducing stress, and reducing caffeine and alcohol consumption are reasonable, low-risk conservative measures for any patient with tinnitus, bothersome or not.[1]
- For patients with genuinely nonbothersome tinnitus, reassurance plus these conservative measures is usually sufficient — avoid over-medicalizing a presentation that does not need aggressive intervention.
What is investigational, not yet standard of care
Transcranial magnetic stimulation has been proposed as a noninvasive treatment for chronic bothersome tinnitus, but it remains available only within research trials and should not be presented to patients as an established, accessible therapy.[1]
Surgical management — rare, and only for a specific treatable cause
Surgery is very rarely used for tinnitus itself, and only when a specific treatable underlying cause is identified: acoustic neuroma resection, endolymphatic sac shunting for Ménière's disease (see the dedicated chapter), stapedectomy for otosclerosis, or tensor tympani/stapedius muscle sectioning for muscular myoclonus.[1] For pulsatile tinnitus with an identified vascular lesion, see Choose Initial Treatment.
Special Populations
Pediatrics
Tinnitus is uncommonly the presenting complaint in children, but the ototoxic-drug risk factors in this chapter remain directly relevant — aminoglycoside courses in neonatal intensive care and cisplatin in pediatric oncology both carry real, and in the case of cisplatin materially higher, ototoxicity risk in young children; see the Hearing Loss chapter's Special Populations for the full pediatric monitoring discussion. When a child does report new tinnitus, take the same history-driven approach (pulsatile versus nonpulsatile, unilateral versus bilateral, ototoxic medication history) rather than assuming it is benign because tinnitus is rare in this age group.
Pregnancy and breastfeeding
Most tinnitus assessment and non-pharmacologic management (reassurance, sound therapy, CBT) is safe and appropriate in pregnancy and breastfeeding. Defer non-urgent imaging where clinically reasonable, and coordinate any genuinely indicated imaging with obstetrics. Aminoglycosides, high-dose salicylates, and cisplatin each carry their own separate pregnancy-specific risk considerations beyond ototoxicity and should be managed by the treating specialist with those in mind; confirm any medication decision against the specific drug's own Drug Database entry.
Older adults
Age is one of the strongest risk factors for tinnitus, and presbycusis raises baseline hearing loss while narrowing the detectable margin before a new ototoxic effect becomes clinically apparent — making a baseline hearing/tinnitus check more valuable, not less, before a planned ototoxic course in this group (see the Hearing Loss chapter). Polypharmacy also raises the real possibility of cumulative or stacked ototoxic exposure — for example, chronic NSAID or high-dose ASA use layered onto an acute aminoglycoside or macrolide course — making a targeted medication review a genuinely useful pharmacist contribution. Comorbid depression and social isolation are also more prevalent in this group and compound the quality-of-life impact of bothersome tinnitus (see below).
Comorbid anxiety, depression, and sleep disturbance — a real, important part of management
When tinnitus is severe enough to significantly affect quality of life, actively screen for and address comorbid anxiety, depression, and sleep disturbance rather than treating them as separate from tinnitus management.[1] Increasing tinnitus severity is inversely associated with quality of life, and mood disorders are among the factors most consistently shown to affect a patient's expected outcome and functional impact.[1] CBT itself has documented benefit for comorbid depression in tinnitus sufferers, and a formally diagnosed comorbid depression or anxiety disorder is a genuine, appropriate indication for a tricyclic antidepressant or SSRI on its own merits (see Choose Initial Treatment) — distinct from, and not to be confused with, using an antidepressant as an unproven attempt to treat the tinnitus percept itself.[1] For any patient expressing hopelessness or suicidal ideation in the context of severe, distressing tinnitus, escalate urgently per the Suicide Risk & Prevention chapter rather than assuming this will resolve with routine reassurance.
Occupational and recreational noise exposure
Patients with significant occupational noise exposure benefit from hearing-conservation counseling and hearing protection as both a prevention and a secondary-prevention measure once tinnitus has developed — cross-reference the Hearing Loss chapter's prevention content for the full discussion.
Monitoring & Follow-Up
Chronic subjective tinnitus
Reassess bothersome tinnitus within a few months of starting any non-pharmacologic therapy (CBT, sound therapy, tinnitus retraining therapy, or hearing aid amplification) — confirm adherence and re-administer a validated tool such as the Tinnitus Handicap Inventory to track functional impact over time rather than relying on an unstructured "is it better?" question alone.[3] Reassess mood and sleep at the same visits, given how closely these track with perceived tinnitus severity (see Special Populations).
Ototoxic drug-induced tinnitus
Systematically ask about tinnitus, subjective hearing change, aural fullness, and dizziness at every clinical contact during a course of a known ototoxic agent — this is a genuinely practical, low-cost complement to formal audiometry, and the pharmacist's specific role is flagging this opportunity and escalating any positive finding promptly rather than assuming someone else will catch it.[3] See the Hearing Loss chapter for the full baseline-and-serial audiometry protocol and timing benchmarks, which this chapter deliberately does not repeat.
Pulsatile tinnitus with an identified structural or vascular cause
Follow-up is directed by the managing specialist (neurotology, neurosurgery, or interventional neuroradiology) per the lesion-specific protocol; the pharmacist's role is supporting medication management around any procedural intervention and reinforcing why the imaging work-up and any subsequent procedure were genuinely necessary, not incidental.
When to re-image or re-refer
A change in tinnitus character (new pulsatility, new asymmetry, or a shift from bilateral to unilateral), progressive or asymmetric hearing loss, or a persistent complaint despite an initially normal work-up are all reasons to revisit the diagnosis rather than assume the original classification still holds — see Treatment Failure/Next Step.
Common Errors to Avoid
- Not asking specifically whether tinnitus is pulsatile or nonpulsatile, and unilateral or bilateral — missing the single most important branch point in the entire work-up.
- Ordering routine imaging for typical bilateral, nonpulsatile tinnitus with a normal exam — low-value, costly, and not supported by current guidance.
- Missing pulsatile tinnitus as a red flag and not pursuing the specific vascular/structural work-up, rather than treating it as routine subjective tinnitus.
- Treating unilateral tinnitus with a normal otoscopic exam as reassuring on its own, rather than pursuing audiology referral and imaging to exclude a vestibular schwannoma.
- Promising a cure for chronic subjective tinnitus rather than honestly setting expectations around reducing impact.
- Reaching for antidepressants, anticonvulsants, anxiolytics, intratympanic medications, or dietary supplements as tinnitus-specific therapy, rather than reserving pharmacotherapy for a genuinely diagnosed comorbid indication.
- Not screening for or actively addressing comorbid anxiety, depression, or sleep disturbance in a patient with bothersome tinnitus.
- Not asking about ototoxic medication history during the tinnitus work-up, missing an actionable, potentially modifiable cause.
- Dismissing tinnitus reported during a course of a known ototoxic agent as an expected nuisance rather than an early, often still-reversible warning sign warranting prompt escalation.
- Assuming aminoglycoside- and salicylate-induced tinnitus behave the same way — missing the genuinely important reversibility contrast between them.
- Not offering a hearing aid evaluation when comorbid hearing loss is present, even when tinnitus itself is the presenting complaint.
- Managing a patient whose tetrad (tinnitus, episodic vertigo, fluctuating hearing loss, aural fullness) actually fits Ménière's disease as routine isolated tinnitus rather than recognizing the pattern and consulting the dedicated chapter.
Clinical Decision Algorithm
Drug Tables
How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page. No agent in this table cures tinnitus itself — the first table identifies genuine ototoxic culprits to recognize and escalate, the second addresses genuine comorbid targets, and the third states plainly what current guidance advises against.
Ototoxic Drug Culprits — Tinnitus as the Earliest Warning Sign
This chapter's centerpiece table. Tinnitus is very often the earliest, most practical bedside sign of ototoxicity from these agents — frequently reported before any change is measurable on formal audiometry. Reversibility genuinely differs by agent; the aminoglycoside-versus-salicylate contrast below is a useful teaching point in its own right.
| Drug | Dose / risk relationship | Adverse effects | Drug interactions / combined risk | Comments |
|---|---|---|---|---|
| Gentamicin | Representative dosing: 5-7 mg/kg IV once daily (extended-interval dosing) or per levels and renal function | Tinnitus often precedes measurable hearing loss; vestibulotoxicity and/or cochleotoxicity, frequently irreversible | Additive, potentially permanent risk with concurrent loop diuretic or glycopeptide (e.g., vancomycin) use — see the Hearing Loss chapter for the full monitoring protocol | Representative aminoglycoside (tobramycin, amikacin, and streptomycin carry the same class risk). Report new tinnitus during any aminoglycoside course immediately, since by the time it is reported the underlying cochlear hair cell injury may already be permanent. |
| Furosemide | High-dose IV use: Per indication; use slow IV infusion rather than rapid bolus when high-dose therapy is genuinely needed | Reversible cochleotoxicity (stria vascularis edema) when used alone; tinnitus and a transient threshold shift are the usual early findings | Additive, potentially permanent ototoxicity with a concurrent aminoglycoside — the single highest-risk combination in this chapter | Risk is concentrated in high-dose IV use, especially rapid bolus; slow infusion reduces risk when a high dose is genuinely needed. Furosemide-alone tinnitus typically resolves within hours to days of stopping or reducing the dose. |
| Acetylsalicylic acid (high dose) | Chronic high-dose/anti-inflammatory dosing: Risk rises with sustained doses of roughly 3-4 g/day or higher, or an elevated serum salicylate concentration, including acute overdose | Tinnitus is classically the earliest and most reliable warning sign, typically with mild-to-moderate, fully reversible hearing loss | Risk compounds with any other ototoxic agent used concurrently | A genuinely useful teaching contrast to the aminoglycoside pattern above: salicylate-induced tinnitus and hearing loss are dose-related and classically fully reversible within 24-72 hours of dose reduction or discontinuation. |
| Cisplatin | Platinum chemotherapy: Dose and schedule per oncology protocol; risk is cumulative-dose dependent | Dose-dependent, often permanent, bilateral high-frequency hearing loss, frequently accompanied by tinnitus | Ototoxic risk is cumulative across chemotherapy cycles; coordinate audiometric monitoring with oncology | Markedly higher risk in children under 5. See the Hearing Loss chapter for the full baseline-and-per-cycle audiometric monitoring protocol. |
| Quinine | Dose-related risk: Prevalence of cinchonism symptoms, including tinnitus, rises directly with quinine dose | Tinnitus is a hallmark early feature of cinchonism, typically appearing 3-6 hours after ingestion alongside nausea, headache, and reversible high-frequency hearing loss | Additive ototoxic risk with other agents in this table | Ototoxicity is dose-related and, in most patients, almost completely reversible with dose reduction or discontinuation — but this should not be assumed automatic with repeated or high-dose exposure. |
| Clarithromycin | Cumulative-dose risk: Not typically seen with a single short course; risk accumulates with repeated or prolonged therapy | Reversible tinnitus and, less commonly, hearing loss | Risk is cumulative-dose related rather than tied to a single short course; azithromycin and erythromycin carry the same class signal | A large cohort study found macrolide use overall carried roughly 25% higher odds of tinnitus, an association that strengthened above a cumulative dose of 14 defined daily doses and was most pronounced with intermediate- and long-acting agents (azithromycin, clarithromycin) rather than short courses. |
Adjunct Pharmacotherapy for Comorbid Symptoms — Not Tinnitus-Specific Therapy
No drug is Health Canada- or FDA-approved specifically to treat tinnitus. The agents below address a genuine comorbid target (sleep, a diagnosed mood disorder) rather than the tinnitus percept itself, and should be presented to patients that way.
| Drug | Dose / risk relationship | Adverse effects | Drug interactions / combined risk | Comments |
|---|---|---|---|---|
| Melatonin | Typical adjunct dose: 3-5 mg PO at bedtime, individualized | Drowsiness, headache, vivid dreams | Additive sedation with other CNS depressants | Some trial evidence supports a modest benefit for tinnitus-associated sleep disturbance specifically; current guidance nonetheless recommends against dietary supplements for tinnitus generally — a genuine tension worth disclosing rather than glossing over. Reasonable as a sleep-focused adjunct, not marketed as a tinnitus cure. |
| Sertraline | Comorbid depression/anxiety: Per standard SSRI dosing for the diagnosed indication | GI upset, sexual dysfunction, insomnia or somnolence | Serotonin syndrome risk with other serotonergic agents | Reasonable when a comorbid depression or anxiety disorder is formally diagnosed alongside tinnitus — treats the diagnosed comorbidity on its own merits, not an unproven tinnitus therapy. |
| Amitriptyline | Comorbid depression/anxiety: Low starting dose, titrated per standard TCA dosing for the diagnosed indication | Anticholinergic effects, sedation, weight gain, QTc prolongation | Additive sedation/anticholinergic burden; use caution in older adults | Similarly reasonable for a formally diagnosed comorbid mood disorder, not as tinnitus-specific pharmacotherapy; caution in older adults given the anticholinergic burden. |
What Current Guidance Recommends Against for Primary Tinnitus
Included here explicitly, with no slug/link, because these are recommendations against a class of use rather than a specific product to verify — each carries its own class-specific adverse-effect burden with no offsetting tinnitus-specific benefit.
| Drug | Dose / risk relationship | Adverse effects | Drug interactions / combined risk | Comments |
|---|---|---|---|---|
| Antidepressants (routine use) | Class-specific (e.g., GI upset, sexual dysfunction, sedation) with no offsetting tinnitus-specific benefit | N/A for this indication | Current guidance recommends against routine use for a primary indication of treating persistent, bothersome tinnitus; reserve for a formally diagnosed comorbid indication (see Adjunct Pharmacotherapy above). | |
| Anticonvulsants (routine use) | Class-specific (e.g., sedation, dizziness, cognitive effects) | N/A for this indication | Current guidance recommends against routine use for a primary indication of treating persistent, bothersome tinnitus. | |
| Anxiolytics (routine use) | Sedation, dependence with repeated use, fall risk | Additive CNS depression with other sedatives | Current guidance recommends against routine use for a primary indication of treating persistent, bothersome tinnitus. | |
| Intratympanic medications (routine use) | Injection-related risks (otalgia, rare perforation) with no established tinnitus-specific benefit | N/A for this indication | Current guidance recommends against routine use for primary tinnitus, distinct from their genuine, established role in other conditions (e.g., sudden sensorineural hearing loss — see the Hearing Loss chapter). | |
| Dietary supplements (ginkgo biloba, zinc, and others) | Variable by supplement; generally modest but not risk-free | Variable; ginkgo biloba carries a bleeding-risk interaction profile | Current guidance recommends against dietary supplements for tinnitus specifically, despite continued patient interest and marketing. |
References
- Approach to tinnitus management — Canadian Family Physician (Wu V, Cooke B, Eitutis S, Simpson MTW, Beyea JA). Can Fam Physician 2018;64(7):491-495
- Pulsatile Tinnitus: A Comprehensive Clinical Approach to Diagnosis and Management — Journal of Clinical Medicine (Pacheco-López S, Martínez-Barbero JP, Busquier-Hernández H, García-Valdecasas-Bernal J, Espinosa-Sánchez JM). J Clin Med 2025;14(13):4428
- Ototoxicity: A Challenge in Diagnosis and Treatment — Journal of Audiology and Otology (Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP). J Audiol Otol 2018;22(2):59-68
- Drug-Induced Ototoxicity: A Comprehensive Review and Reference Guide — Pharmacotherapy (Rizk HG, Lee JA, Liu YF, Endriukaitis L, Isaac JL, Bear M). Pharmacotherapy 2020;40(12):1265-1275
- Aminoglycoside-Induced Cochleotoxicity: A Review — Frontiers in Cellular Neuroscience (Jiang M, Karasawa T, Steyger PS). Front Cell Neurosci 2017;11:308
- Cinchonism — StatPearls [Internet] (Bykowski A, Logan TD). StatPearls Publishing, updated September 4, 2023
- Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss — Journal of Antimicrobial Chemotherapy (Vanoverschelde A, Oosterloo BC, Ly NF, Ikram MA, Goedegebure A, Stricker BH, Lahousse L). J Antimicrob Chemother 2021;76(10):2708-2716
- Clinical Practice Guideline: Tinnitus — Otolaryngology-Head and Neck Surgery, American Academy of Otolaryngology-Head and Neck Surgery Foundation (Tunkel DE, Bauer CA, Sun GH, et al.). Otolaryngol Head Neck Surg 2014;151(2 Suppl):S1-S40
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.